[
THE INVESTOR]
Ahn-gook Pharmaceutical announced on Aug. 17 that it has completed a nonclinical study on UAI-101, an 11B-HSD1 inhibitor, and will apply for phase 1 clinical trials to the European Medicines Agency by the end of this year.
This new drug candidate is a new type of therapy that will selectively inhibit 11B-HSD1, an enzyme that controls cortisol that regulates metabolism and thus can cause metabolic-related conditions including diabetes, obesity and dyslipidemia.
 |
Ahn-gook Pharmaceutical's R&D center in Seoul |
Unlike existing treatments, however, it does not have side effects such as cardiovascular disease or weight gain, according to the company.
By Hwang You-mee (
glamazon@heraldcorp.com)
